Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma.

Hari K NarayanMary E PuttNikitha KosarajuAlejandro PazShivani BhattTheodore PlappertLaura Mercer-RosaSaro H ArmenianAmi V DesaiRichard B WomerBonnie Ky

Published in: Open heart (2019)

Early, sustained alterations in LV structure and function occur in children with sarcoma after high-dose doxorubicin, with adverse changes and protective effects of dexrazoxane more pronounced in females as compared with males. Dexrazoxane may have sex-specific cardioprotective effects.

Keyphrases

high dose
young adults
drug delivery
cancer therapy
low dose
stem cell transplantation
radiation induced
adverse drug